UPCC 24116: A Phase II Pilot Trial of Hydroxychloroquine Everolimus or the Combination for Prevention of Recurrent Breast Cancer
Enrolling By Invitation
99 years or below
All
Phase
2
60 participants needed
1 Location
Brief description of study
The main purpose of this study is to:
1) determine the feasibility of giving hydroxychloroquine, everolimus or the combination to people with disseminated tumor cells detected in their bone marrow.
2) determine how tolerable these drugs are in people who have completed treatment for breast cancer.
3) determine how well these drugs do at reducing the number of disseminated tumor cells in the bone marrow.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: TBD, tbd, tbd
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 826253
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
